Cartesian Therapeutics, INC Schedule 13G passive stakes

Barclays PLC has filed a Schedule 13G, reporting beneficial ownership of 5.99% of Cartesian Therapeutics Inc. common stock as of June 30, 2026.

JPMorgan Chase & Co. has reported a beneficial ownership of 4.8% in Cartesian Therapeutics, Inc., holding 1,486,252 shares.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 3.0% of Cartesian Therapeutics' common stock as of March 31, 2026.

Investment firm Squarepoint and its affiliates have reported a passive 8.3% beneficial ownership stake in Cartesian Therapeutics, Inc. common stock.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have reported a beneficial ownership of 5.3% in Cartesian Therapeutics Inc. as of December 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting an 8.3% beneficial ownership stake in Cartesian Therapeutics Inc.'s common stock.

JPMorgan Chase & Co. has filed a Schedule 13G, revealing a beneficial ownership of 6.1% in Cartesian Therapeutics, Inc.'s common stock as of March 31, 2025.

FMR LLC and its affiliate Abigail P. Johnson have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 9.4% of Cartesian Therapeutics Inc.'s common stock as of December 31, 2024.